CL2023003345A1 - Composición farmacéutica para prevenir o tratar la fibrosis - Google Patents

Composición farmacéutica para prevenir o tratar la fibrosis

Info

Publication number
CL2023003345A1
CL2023003345A1 CL2023003345A CL2023003345A CL2023003345A1 CL 2023003345 A1 CL2023003345 A1 CL 2023003345A1 CL 2023003345 A CL2023003345 A CL 2023003345A CL 2023003345 A CL2023003345 A CL 2023003345A CL 2023003345 A1 CL2023003345 A1 CL 2023003345A1
Authority
CL
Chile
Prior art keywords
pharmaceutical composition
prevent
treat fibrosis
fibrosis
component
Prior art date
Application number
CL2023003345A
Other languages
English (en)
Inventor
Jeong Bae Da
Hee Lee Caroline
Jae Cho Min
Young Park Min
Hyeon Kim Ji
Seok Park Joon
Original Assignee
Daewoong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daewoong Pharmaceutical Co Ltd filed Critical Daewoong Pharmaceutical Co Ltd
Publication of CL2023003345A1 publication Critical patent/CL2023003345A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a una composición farmacéutica cuyo uso puede resultar de utilidad para prevenir o tratar la fibrosis. De acuerdo con la presente invención, existe la característica de que el efecto preventivo o terapéutico de la fibrosis puede potenciarse utilizando el primer componente y el segundo componente en combinación.
CL2023003345A 2021-05-13 2023-11-09 Composición farmacéutica para prevenir o tratar la fibrosis CL2023003345A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
KR20210062252 2021-05-13

Publications (1)

Publication Number Publication Date
CL2023003345A1 true CL2023003345A1 (es) 2024-06-07

Family

ID=84029268

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2023003345A CL2023003345A1 (es) 2021-05-13 2023-11-09 Composición farmacéutica para prevenir o tratar la fibrosis

Country Status (18)

Country Link
US (1) US20240238278A1 (es)
EP (1) EP4338734A4 (es)
JP (1) JP7762224B2 (es)
KR (1) KR20220154616A (es)
CN (1) CN117320718A (es)
AR (2) AR125886A1 (es)
AU (1) AU2022274469B2 (es)
BR (1) BR112023023670A2 (es)
CA (1) CA3213455A1 (es)
CL (1) CL2023003345A1 (es)
CO (1) CO2023015482A2 (es)
EC (1) ECSP23086047A (es)
JO (1) JOP20230279A1 (es)
MX (1) MX2023013405A (es)
PE (1) PE20241171A1 (es)
TW (1) TW202310839A (es)
WO (1) WO2022240036A1 (es)
ZA (1) ZA202310049B (es)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0917013A2 (pt) * 2008-08-11 2016-02-16 Glaxosmithkline Llc métodos para tratar doenças alérgicas e outras condições inflamatórias, e para tratar ou prevenir doença, composto, composição farmacêutica, e, uso de um composto
AR110963A1 (es) 2017-02-07 2019-05-22 Dae Woong Pharma Compuestos heterocíclicos, su método de preparación y composición farmacéutica que los comprende
CN112040950A (zh) * 2018-03-19 2020-12-04 上海偕怡医药科技有限公司 治疗特发性肺纤维化的方法和组合物
US20210205253A1 (en) * 2018-05-31 2021-07-08 The Asan Foundation Use Of Stearic Acid For Preventing Or Treating Pulmonary Fibrosis
BR112023019668A2 (pt) * 2021-05-13 2023-11-28 Daewoong Pharmaceutical Co Ltd Composição farmacêutica para prevenir ou tratar fibrose
US20240307365A1 (en) * 2021-07-23 2024-09-19 Daewoong Pharmaceutical Co., Ltd. Pharmaceutical Composition for Preventing or Treating Systemic Sclerosis

Also Published As

Publication number Publication date
JP7762224B2 (ja) 2025-10-29
AR125886A1 (es) 2023-08-23
CA3213455A1 (en) 2022-11-17
KR20220154616A (ko) 2022-11-22
US20240238278A1 (en) 2024-07-18
ZA202310049B (en) 2025-06-25
EP4338734A4 (en) 2025-05-07
EP4338734A1 (en) 2024-03-20
AU2022274469A1 (en) 2023-09-21
JOP20230279A1 (ar) 2023-11-02
CN117320718A (zh) 2023-12-29
PE20241171A1 (es) 2024-05-28
ECSP23086047A (es) 2023-12-29
BR112023023670A2 (pt) 2024-01-30
WO2022240036A1 (ko) 2022-11-17
MX2023013405A (es) 2023-11-27
CO2023015482A2 (es) 2023-11-30
TW202310839A (zh) 2023-03-16
AU2022274469B2 (en) 2025-06-05
JP2024516021A (ja) 2024-04-11
AR125885A1 (es) 2023-08-23

Similar Documents

Publication Publication Date Title
CL2021002100A1 (es) Combinación farmacéutica que comprende tno155 y un inhibidor de pd–1.
BR112021017350A2 (pt) Combinação de conjugado de anticorpo-derivado de pirrolobenzodiazepina e inibidor de parp
MX2023009521A (es) Compuesto de quinazolina para inducir la degradacion de la proteina kras mutante g12d.
PH12022550438A1 (en) N4-hydroxycytidine and derivatives and anti-viral uses related thereto
CR20190403A (es) Una composición farmacéutica que comprende un anticuerpo anti-c5 contra una enfermedad relacionada con c5 y un producto de la misma
BRPI1012219C1 (pt) produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina
MX2021000516A (es) Composicion farmaceutica para usarse en el tratamiento o prevencion de una enfermedad relacionada con c5 y metodo para tratar o prevenir una enfermedad relacionada con c5.
DOP2021000039A (es) Administración prolongada de lasmiditan por la noche para la prevención de la migraña
MX2022015900A (es) Inhibidores de alk2 para el tratamiento de la anemia.
BR112022018396A2 (pt) Método de tratamento ou prevenção para insuficiência cardíaca crônica
WO2022020353A3 (en) Methods and compositions for treatment and prevention of coronavirus infection
BR112022022305A2 (pt) Combinação farmacêutica que compreende tno155 e nazartinibe
BR112022015800A2 (pt) Tratamento de colangite biliar primária com elafibranor
CO2021005797A2 (es) Métodos y formulaciones para tratar náuseas y vómitos inducidos por quimioterapia
BR112022010750A2 (pt) Método para tratar câncer usando célula adjuvante artificial (aavc)
CL2021000107A1 (es) Métodos de tratamiento de hfpef empleando dapagliflozina y composiciones que comprenden la misma
CL2023003345A1 (es) Composición farmacéutica para prevenir o tratar la fibrosis
BR112018072298A2 (pt) tratamento de infecções pelo vírus da zika usando inibidores da alfa-glicosidase
CO2025006082A2 (es) Compuestos y su uso para el tratamiento de hemoglobinopatías
MX2023005829A (es) Combinaciones farmaceuticas para tratar el cancer.
AR124639A1 (es) Composición para el tratamiento de una enfermedad vascular, la prevención de una enfermedad vascular, el tratamiento de la hipertensión, o la prevención de la hipertensión
MX2021006654A (es) Uso de extracto de cocculus hirsutus para tratar dengue.
MX2021004418A (es) Derivados de 4 pirazin 2 ilmetil-morfolina y su uso como medicamento.
AR054368A1 (es) Metodo para tratar hiperlipidemia
MX2023003401A (es) Composicion farmaceutica para prevenir o tratar enfermedad hepatica colestasica, que contiene beta-lapachona como ingrediente activo.